Fasedienol (PH94B)

About Vistagen Therapeutics

Vistagen is advancing a novel neuroscience platform centered on pherines, which are neuroactive nasal sprays designed to modulate the olfactory-amygdala neural circuits, offering a potential rapid-onset treatment for mood and anxiety disorders without systemic exposure. Its lead candidate, fasedienol (PH94B), is in Phase 3 development for social anxiety disorder, and it has multiple other clinical-stage assets for major depressive disorder and postpartum anxiety. The company's strategy focuses on developing non-systemic, non-addictive alternatives to current standard-of-care treatments, positioning it in a high-value segment of the CNS therapeutics market.

About Vistagen Therapeutics

Vistagen is advancing a novel neuroscience platform centered on pherines, which are neuroactive nasal sprays designed to modulate the olfactory-amygdala neural circuits, offering a potential rapid-onset treatment for mood and anxiety disorders without systemic exposure. Its lead candidate, fasedienol (PH94B), is in Phase 3 development for social anxiety disorder, and it has multiple other clinical-stage assets for major depressive disorder and postpartum anxiety. The company's strategy focuses on developing non-systemic, non-addictive alternatives to current standard-of-care treatments, positioning it in a high-value segment of the CNS therapeutics market.

Therapeutic Areas